Antibacterial Mouthwash for Pharyngeal Gonorrhea Prevention
Status:
Not yet recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
This study aims to determine acceptability and preliminary efficacy of daily use of an
antibacterial mouthwash as compared to a placebo mouthwash in reducing the incidence of
pharyngeal gonorrhea among a cohort of HIV-positive and high risk HIV-negative men.
Investigators plan to test the following hypotheses:
1. Participants will maintain a high level of adherence and satisfaction with daily
mouthwash use. Furthermore, the investigators hypothesize that barriers to adherence
will include structural factors such as unstable housing and individual level factors
such as substance use.
2. Participants receiving the antibacterial mouthwash will have a lower incidence of
pharyngeal gonorrhea as compared to participants receiving the placebo mouthwash.
Furthermore, the investigators hypothesize that these reductions will remain even after
adjusting for other factors such as HIV-status and substance use.